Explore Global Companies & Account Intelligence

Cardiologie Centra Nederland (CCN) is een organisatie van zelfstandige behandelcentra voor cardiologische zorg waar patiënten met hart- en vaatziekten en verwijzers meteen terecht kunnen. We staan voor de beste innovatieve en persoonlijke cardiovasculaire zorg met optimale service en persoonlijke begeleiding. In Nederland zijn momenteel 12 vestigingen te vinden: Almere - Amsterdam AMC - Amsterdam Geervliet - Amsterdam West - Amsterdam Zuid - Blaricum - Hoogvliet - Utrecht - Voorschoten - IJmuiden - Middelburg - Dokkum De patiënt kan na verwijzing van de huisarts al binnen 24 uur bij ons terecht. Alle nodige onderzoeken vinden diezelfde dag binnen 2 uur plaats door uiterst bekwame cardiologen en specialisten. Aan het einde van de onderzoeken bespreekt de cardioloog de diagnose met de patiënt en stelt eventueel een behandelplan op. Ook de verwijzer krijgt dezelfde dag terugkoppeling. Binnen CCN is voor ieder deelspecialisme binnen de cardiologie een cardioloog beschikbaar. Daarnaast zijn onze cardiologen actief bezig met de preventie van hart- en vaatziekten. Wat bieden wij? - Totaal concept: onderzoeken, diagnostiek en behandeling - Samenwerking met gerenommeerde ziekenhuizen - 24/7 bereikbaar voor patiënten en verwijzers - Persoonlijke zorg - Verzekerde zorg (contracten met alle zorgverzekeraars)

CARDIOLOGY CONSULTANTS MEDICAL GROUP OF THE VALLEY is a medical practice company based out of 18370 BURBANK BLVD., SUITE 707, TARZANA, California, United States.

Cardiology news.

Comprehensive enterprise dossier available in global intelligence registry.

At Cardiome, our vision is 'To improve patients' quality of life by making superior medicines accessible'. In order to achieve this, we live by the values of Committed, Respectful, Multi-Cultural and Ethical. Cardiome Pharma Corp. is a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Cardiome develops, acquires and commercializes brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio® (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess® (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, and Esmocard® and Esmocard Lyo® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications. Cardiome's pipeline of product candidates includes Trevyent®, a drug device combination that is designed to deliver Remodulin® (treprostinil) the world's leading treatment for pulmonary arterial hypertension. Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com. Looking to join Cardiome's team? Check out our careers page at www.cardiome.com/careers/

Comprehensive enterprise dossier available in global intelligence registry.

We, at Cardionovum have one common mission. Maintaining our technology leadership and realising innovative medical device concepts. For the best patient treatment, today as well as in the future. Cardionovum feels competent for further developments in leading edge technologies. Our clinically proven products set the benchmark for further medical therapy solutions. Cardionovum has a full R & D portfolio and promises more exceptional medical devices to be launched into the medical market to keep up with and set therapeutical trends in cardiovascular medicine. In 2007 Dr. Michael Orlowski introduced the first CE mark approved Drug-Eluting Balloon Dilatation Catheter to the market. With the first DCB market introduction the founder of Cardionovum contributed significantly to the establishment of a new medical device therapy to treat coronary and peripheral artery disease effectively. The treatment of coronary stent-associated patient problems, like in-stent restenosis (ISR), and the treatment of peripheral artery lesions by a DCB have become the preferred treatment standard. Cardionovum consists of R & D, Sales and Marketing staff, with the longest and most profound experience, in developing of clinically advanced DCB and DES cardiovascular devices.

CardioQuip (www.CardioQuip.com) is a perfusion equipment provider based in College Station, Texas. Originally established as a refurbisher of perfusion devices, CardioQuip leveraged years of conversations with surgeons, biomeds, and perfusionists to design and manufacture their first cooler heater in 2011. With the introduction of the MCH-1000(i), CardioQuip launched a new generation of cooler-heaters, featuring intuitive design, simplified cleaning, and accurate temperature control. Two years later, CardioQuip released the MCH-1000(m) which offers full size performance in a compact footprint. CardioQuip proudly designs and manufactures all of its equipment in the USA.

Comprehensive enterprise dossier available in global intelligence registry.

Early detection of heart attacks and strokes, before it's too late. (e.g. in time to treat medically instead of waiting until a surgical intervention is your only option). CardioRisk Laboratories is a national service company offering Carotid Intima Media Thickness (CIMT) screening to primary care physicians, cardiologists, and other health care professionals and patients to help them identify and reduce cardiac, and cerebrovascular events in their patients. A CIMT test provides patients with an assessment of their individual risk for heart attack, stroke, and other ischemic events. CardioRisk provides this valuable assessment of heart attack and stroke risk at physician offices throughout the United States. We support pharmaceutical, clinical outcome, and epidemiologic studies where CIMT is used to monitor disease progression or as a surrogate for clinical events. In a 10-year, 100,000 person-year longitudinal study, IMT technology caught 98.6% of the heart attacks and strokes BEFORE they occurred. That is better than a home pregnancy test. The CardioRisk CIMT exam was scientifically designed, validated via peer-reviewed published literature demonstrating CardioRisk's unique protocol which specializes in reproducibility, sensitivity, and specificity for heart disease. The test in non-invasive, requires no radiation exposure, no disrobing is necessary and there are no needle sticks or any pain involved. Call CardioRisk to arrange to be tested in your area.

Early detection of heart attacks and strokes, before it's too late. (e.g. in time to treat medically instead of waiting until a surgical intervention is your only option). CardioRisk Laboratories is a national service company offering Carotid Intima Media Thickness (CIMT) screening to primary care physicians, cardiologists, and other health care professionals and patients to help them identify and reduce cardiac, and cerebrovascular events in their patients. A CIMT test provides patients with an assessment of their individual risk for heart attack, stroke, and other ischemic events. CardioRisk provides this valuable assessment of heart attack and stroke risk at physician offices throughout the United States. We support pharmaceutical, clinical outcome, and epidemiologic studies where CIMT is used to monitor disease progression or as a surrogate for clinical events. In a 10-year, 100,000 person-year longitudinal study, IMT technology caught 98.6% of the heart attacks and strokes BEFORE they occurred. That is better than a home pregnancy test. The CardioRisk CIMT exam was scientifically designed, validated via peer-reviewed published literature demonstrating CardioRisk's unique protocol which specializes in reproducibility, sensitivity, and specificity for heart disease. The test in non-invasive, requires no radiation exposure, no disrobing is necessary and there are no needle sticks or any pain involved. Call CardioRisk to arrange to be tested in your area.

Under the T-Zone Pro umbrella are divisions: - Bioflex Australia - T-Zone Health - CardioTech Our Principals are pioneers in the fitness industry - importing, manufacturing and distributing quality products throughout Australia for nearly 30 years.